"Allogene Shifts Gears with New Strategy and Partnerships in Cell Therapy for Blood Cancer Amid Workforce Reduction"
Originally Published 2 years ago — by STAT
Allogene Therapeutics is altering its development strategy for ALLO-501A, an off-the-shelf cell therapy for blood cancer, due to intense competition from personalized CAR-T treatments. The company is discontinuing two ongoing clinical trials for patients with advanced-stage lymphoma and instead will initiate a new study targeting newly diagnosed high-risk lymphoma patients. This shift aims to position ALLO-501A more effectively in the competitive blood cancer treatment landscape.